Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. whilyas

WHILYAS

Wound healing ILYA-style

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 WHILYAS project word cloud

Explore the words cloud of the WHILYAS project. It provides you a very rough idea of what is the project "WHILYAS" about.

billion    act    sciences    translates    life    healed    site    people    eur    amputation    patients    small    66    genetically    library    healing    topical    water    15    30    mortality    ilya100tm    chronic    microbiology    therapeutic    difficulties    total    modified    chemokine    efficiency    candidate    alarming    approx    tackling    heal    expressing    alone    lactobacillus    budget    18    overuse    drug    manner    2011    innovation    world    segment    cxcl12    million    limb    bioreactors    diabetic    ulcers    stems    foot    quality    swedish    dfus    local    least    possibly    dressings    substantial    wound    acid    accelerate    wounds    market    cancers    drugs    spend    4    countries    debridement    healthcare    group    administration    prior    annual    human    savings    ev100    tissue    university    agricultural    endogenously    implying    limited    industrialized    unmet    medical    bacteria    personal    complications    proteins    lactic    11    rate    revived    first    dried    mechanical    antibiotics    care    faster    cheaper    treatment    uppsala    cagr    immunophysiology    regeneration    social    chosen    freeze    diabetes    designed    2014    delivered   

Project "WHILYAS" data sheet

The following table provides information about the project.

Coordinator		 ILYA PHARMA AB 

Organization address
address: DAG HAMMARSKIOLDS VAG 30
city: UPPSALA
postcode: 752 37
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Sweden [SE]
 Project website http://www.ilyapharma.se
 Total cost 2˙992˙575 €
 EC max contribution 2˙992˙575 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ILYA PHARMA AB SE (UPPSALA) coordinator 2˙992˙575.00

Map

 Project objective

The objective of the project is to develop the EV100 drug candidate to heal chronic wounds in patients with diabetes in a better, faster, and cheaper manner than any method available today. We have chosen to target wounds in patients with diabetes, due to a large unmet medical need in this group. Today, 18% of people with diabetes have a chronic wound which translates into at least 6 million people in Europe alone. One of the complications of diabetes, diabetic foot ulcers (DFUs) often result in limb amputation. The mortality rate after an amputation is 30% within the first year, which is similar to several cancers. Even more alarming, treatment is today limited to mechanical debridement, use of different dressings, and a substantial overuse of antibiotics. Industrialized countries spend 2-4% of total healthcare budget on chronic wounds. The market for wound care is EUR 15 billion and the segment of DFUs is in the range of EUR 1.5 billion, with 11% CAGR 2011-2014. We have designed and built genetically modified lactic acid bacteria that accelerate wound healing with a unique efficiency. Human therapeutic proteins endogenously involved in tissue regeneration are continuously delivered on site in wounds by the lactic acid bacteria that act like small local bioreactors. EV100 is one of the candidate drugs in our library using Ilya100TM technology and is Lactobacillus expressing the human chemokine CXCL12. The Lactobacillus are freeze-dried and revived with water just prior to topical administration. The innovation stems from world-leading medical research in immunophysiology and microbiology at Uppsala University and the Swedish University of Agricultural Sciences. With EV100 chronic wounds could possibly be healed approx. 66% faster, implying annual cost savings of EUR 6 billion in the US and Europe and tackling all the personal and social difficulties associated with chronic wounds, increasing the quality of life of patients all around the world.

 Deliverables

List of deliverables.
An updated plan for the exploitation and dissemination of the results Documents, reports 2020-02-11 12:59:43
ORDP - Open Research Data Pilot Open Research Data Pilot 2020-02-11 12:59:43

Take a look to the deliverables list in detail:  detailed list of WHILYAS deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Evelina Vågesjö, Emelie Öhnstedt, Anneleen Mortier, Hava Lofton, Fredrik Huss, Paul Proost, Stefan Roos, Mia Phillipson
Accelerated wound healing in mice by on-site production and delivery of CXCL12 by transformed lactic acid bacteria
published pages: 1895-1900, ISSN: 0027-8424, DOI: 10.1073/pnas.1716580115 		Proceedings of the National Academy of Sciences 115/8 2020-02-11
2019 Emelie Öhnstedt, Hava Lofton Tomenius, Evelina Vågesjö, Mia Phillipson
The discovery and development of topical medicines forwound healing
published pages: , ISSN: 1746-045X, DOI: 		Expert Opinion on Drug Discovery 2020-02-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "WHILYAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "WHILYAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More